ZA200209966B - Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders. - Google Patents
Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders. Download PDFInfo
- Publication number
- ZA200209966B ZA200209966B ZA200209966A ZA200209966A ZA200209966B ZA 200209966 B ZA200209966 B ZA 200209966B ZA 200209966 A ZA200209966 A ZA 200209966A ZA 200209966 A ZA200209966 A ZA 200209966A ZA 200209966 B ZA200209966 B ZA 200209966B
- Authority
- ZA
- South Africa
- Prior art keywords
- sulfonyl
- phenyl
- toluene
- fluoro
- pyrrolidin
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title claims description 10
- 208000025966 Neurological disease Diseases 0.000 title claims description 10
- FDAMVVHYWSPPFN-UHFFFAOYSA-N 2-sulfonylpyrrolidine Chemical class O=S(=O)=C1CCCN1 FDAMVVHYWSPPFN-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 145
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 31
- -1 N-hydroxy-amidino Chemical group 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 230000001154 acute effect Effects 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 10
- 206010034010 Parkinsonism Diseases 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 10
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 229930195712 glutamate Natural products 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- 208000020564 Eye injury Diseases 0.000 claims description 5
- 206010019196 Head injury Diseases 0.000 claims description 5
- 208000010496 Heart Arrest Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000013016 Hypoglycemia Diseases 0.000 claims description 5
- 206010021143 Hypoxia Diseases 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000007101 Muscle Cramp Diseases 0.000 claims description 5
- 206010057852 Nicotine dependence Diseases 0.000 claims description 5
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 5
- 208000017442 Retinal disease Diseases 0.000 claims description 5
- 206010038923 Retinopathy Diseases 0.000 claims description 5
- 208000005392 Spasm Diseases 0.000 claims description 5
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 5
- 206010046543 Urinary incontinence Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 230000036770 blood supply Effects 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000003925 brain function Effects 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 230000036461 convulsion Effects 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 201000005040 opiate dependence Diseases 0.000 claims description 5
- 230000035935 pregnancy Effects 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 4
- OYWCGMXECLMJCI-UHFFFAOYSA-N 3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propan-1-ol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCO OYWCGMXECLMJCI-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims description 2
- JAZSKQKUTMYRPI-UHFFFAOYSA-N 1-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]pyrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCN1N=CC=C1 JAZSKQKUTMYRPI-UHFFFAOYSA-N 0.000 claims description 2
- OKWCHLSDQGQINZ-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-(2-methoxyethyl)-1-(4-methylphenyl)sulfonylpyrrolidine Chemical compound COCCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 OKWCHLSDQGQINZ-UHFFFAOYSA-N 0.000 claims description 2
- WLBSAJCQKQSTDU-QUCCMNQESA-N 5-[2-[(2r,5s)-5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]ethyl]-2-methyltetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1[C@H](C=2C=CC(F)=CC=2)CC[C@@H]1CCC1=NN(C)N=N1 WLBSAJCQKQSTDU-QUCCMNQESA-N 0.000 claims description 2
- IOEDXWSUIPWQPZ-UHFFFAOYSA-N 5-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]-2-methyltetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCC1=NN(C)N=N1 IOEDXWSUIPWQPZ-UHFFFAOYSA-N 0.000 claims description 2
- ITKKZVCTOPQUCG-UHFFFAOYSA-N 5-[4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]butyl]-1-methyltetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCCC1=NN=NN1C ITKKZVCTOPQUCG-UHFFFAOYSA-N 0.000 claims description 2
- IJESRHOOMJWHDN-UHFFFAOYSA-N 5-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]pentanamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCCC(N)=O IJESRHOOMJWHDN-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- COEHUBIWANIJLM-UHFFFAOYSA-N [5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]methanamine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CN COEHUBIWANIJLM-UHFFFAOYSA-N 0.000 claims description 2
- DVBVAMKDJZBOMF-UHFFFAOYSA-N n-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]methanesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCNS(C)(=O)=O DVBVAMKDJZBOMF-UHFFFAOYSA-N 0.000 claims description 2
- CSSQEGIKGYYQFZ-UHFFFAOYSA-N n-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]propanamide Chemical compound CCC(=O)NCCCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 CSSQEGIKGYYQFZ-UHFFFAOYSA-N 0.000 claims description 2
- WOZCFSQKEWSSBW-UHFFFAOYSA-N n-[5-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]pentyl]acetamide Chemical compound CC(=O)NCCCCCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 WOZCFSQKEWSSBW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims 3
- CUGJJAHJRATQLU-UNMCSNQZSA-N (2s,5s)-2-(4-fluorophenyl)-5-(4-methoxybutyl)-1-(4-methylphenyl)sulfonylpyrrolidine Chemical compound N1([C@@H](CC[C@@H]1CCCCOC)C=1C=CC(F)=CC=1)S(=O)(=O)C1=CC=C(C)C=C1 CUGJJAHJRATQLU-UNMCSNQZSA-N 0.000 claims 1
- AWOFSYWHIBZQOY-UHFFFAOYSA-N 1-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]-1,2,4-triazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCN1N=CN=C1 AWOFSYWHIBZQOY-UHFFFAOYSA-N 0.000 claims 1
- UVTGRFMCXIBWJT-UHFFFAOYSA-N 1-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]imidazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCN1C=NC=C1 UVTGRFMCXIBWJT-UHFFFAOYSA-N 0.000 claims 1
- KEHLGACDTOWPEM-UHFFFAOYSA-N 1-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]tetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCN1N=NN=C1 KEHLGACDTOWPEM-UHFFFAOYSA-N 0.000 claims 1
- MWZDIEIXRBWPLG-UHFFFAOYSA-N 1-methyl-1,2,4-triazole Chemical compound CN1C=NC=N1 MWZDIEIXRBWPLG-UHFFFAOYSA-N 0.000 claims 1
- OROSZBHHNYBFGL-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-(3-methoxypropyl)-1-(4-methylphenyl)sulfonylpyrrolidine Chemical compound COCCCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 OROSZBHHNYBFGL-UHFFFAOYSA-N 0.000 claims 1
- FZHKLHAKKSQZNR-UHFFFAOYSA-N 2-[2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]ethyl]-1,3,4-oxadiazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCC1=NN=CO1 FZHKLHAKKSQZNR-UHFFFAOYSA-N 0.000 claims 1
- QOWWGLNZOZKLEH-UHFFFAOYSA-N 2-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]-5-methyl-1,3,4-oxadiazole Chemical compound O1C(C)=NN=C1CCCC1N(S(=O)(=O)C=2C=CC(C)=CC=2)C(C=2C=CC(F)=CC=2)CC1 QOWWGLNZOZKLEH-UHFFFAOYSA-N 0.000 claims 1
- YIYRCVKXJVILLE-UHFFFAOYSA-N 2-[4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]butyl]tetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCCN1N=NC=N1 YIYRCVKXJVILLE-UHFFFAOYSA-N 0.000 claims 1
- MNGQWDRNGZEIAC-MJGOQNOKSA-N 3-[(2r,5s)-5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propanamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1[C@H](C=2C=CC(F)=CC=2)CC[C@@H]1CCC(N)=O MNGQWDRNGZEIAC-MJGOQNOKSA-N 0.000 claims 1
- XELWWSULVWYGAK-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]butan-1-ol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCCO XELWWSULVWYGAK-UHFFFAOYSA-N 0.000 claims 1
- MRYZDAPMTGIGPS-UHFFFAOYSA-N 5-[2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]ethyl]-1,3-oxazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCC1=CN=CO1 MRYZDAPMTGIGPS-UHFFFAOYSA-N 0.000 claims 1
- RVLPLHYYHNALDY-UHFFFAOYSA-N 5-[2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]ethyl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(CCC2N(C(CC2)C=2C=CC(F)=CC=2)S(=O)(=O)C=2C=CC(C)=CC=2)=N1 RVLPLHYYHNALDY-UHFFFAOYSA-N 0.000 claims 1
- HWQRNWYHJIXTJU-GMAHTHKFSA-N n-[3-[(2s,5s)-5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]cyclopropanecarboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1[C@H](C=2C=CC(F)=CC=2)CC[C@@H]1CCCNC(=O)C1CC1 HWQRNWYHJIXTJU-GMAHTHKFSA-N 0.000 claims 1
- QNRRDWIZVZZKKP-UHFFFAOYSA-N n-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NCCCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 QNRRDWIZVZZKKP-UHFFFAOYSA-N 0.000 claims 1
- HKTBBDDKKRQURM-UHFFFAOYSA-N n-[4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]butyl]acetamide Chemical compound CC(=O)NCCCCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 HKTBBDDKKRQURM-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 69
- 238000007429 general method Methods 0.000 description 48
- 239000007787 solid Substances 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000002425 crystallisation Methods 0.000 description 21
- 230000008025 crystallization Effects 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000012230 colorless oil Substances 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 15
- 238000010626 work up procedure Methods 0.000 description 15
- 230000010933 acylation Effects 0.000 description 13
- 238000005917 acylation reaction Methods 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 238000005984 hydrogenation reaction Methods 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000000969 carrier Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 6
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- PRIBOMLXYUNPRO-UHFFFAOYSA-N [5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]methanol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CO PRIBOMLXYUNPRO-UHFFFAOYSA-N 0.000 description 5
- 230000021736 acetylation Effects 0.000 description 5
- 238000006640 acetylation reaction Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 229940080818 propionamide Drugs 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- QZZFVVSDYJNMBF-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carbonitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C#N QZZFVVSDYJNMBF-UHFFFAOYSA-N 0.000 description 4
- OUJTWYNXLSBFEG-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C(O)=O OUJTWYNXLSBFEG-UHFFFAOYSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- JOIHCQYGOALRSU-UHFFFAOYSA-N methyl 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 JOIHCQYGOALRSU-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 3
- WRRPLROSNODLMW-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propanenitrile Chemical compound N#CC(C)C1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 WRRPLROSNODLMW-UHFFFAOYSA-N 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 3
- JBJBOVZRCJOYBR-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carbonyl chloride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C(Cl)=O JBJBOVZRCJOYBR-UHFFFAOYSA-N 0.000 description 3
- YQNIMNMQEIDPNH-UHFFFAOYSA-N 5-(4-fluorophenyl)-n'-hydroxy-1-(4-methylphenyl)sulfonylpyrrolidine-2-carboximidamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C(=N)NO YQNIMNMQEIDPNH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229940049906 glutamate Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- OCNYVMWUOOLUOA-UHFFFAOYSA-N methyl 5-(4-fluorophenyl)-3,4-dihydro-2h-pyrrole-2-carboxylate Chemical compound COC(=O)C1CCC(C=2C=CC(F)=CC=2)=N1 OCNYVMWUOOLUOA-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- WJSCSARPZBOUNT-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]-n'-hydroxyethanimidamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CC(=N)NO WJSCSARPZBOUNT-UHFFFAOYSA-N 0.000 description 2
- OZPUJNYMLIXOQN-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]acetonitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CC#N OZPUJNYMLIXOQN-UHFFFAOYSA-N 0.000 description 2
- FSJDACWSOSYCFC-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]pentanenitrile Chemical compound CCCC(C#N)C1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 FSJDACWSOSYCFC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- MXVWFEPLCQAQRB-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonyl-n-propylpyrrolidin-2-amine Chemical compound CCCNC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 MXVWFEPLCQAQRB-UHFFFAOYSA-N 0.000 description 2
- XCZBCIVLBIFYLB-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carbaldehyde Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C=O XCZBCIVLBIFYLB-UHFFFAOYSA-N 0.000 description 2
- PCXJFVQHSSLJRJ-UHFFFAOYSA-N 5-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]-2h-tetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C1=NNN=N1 PCXJFVQHSSLJRJ-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- HZSXBQVEEPVWIB-UHFFFAOYSA-N diethyl 2-acetamido-2-[3-(4-fluorophenyl)-3-oxopropyl]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)(NC(C)=O)CCC(=O)C1=CC=C(F)C=C1 HZSXBQVEEPVWIB-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- SYTIHPKKCPINOH-UHFFFAOYSA-N methyl 3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propanoate Chemical compound COC(=O)CCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 SYTIHPKKCPINOH-UHFFFAOYSA-N 0.000 description 2
- GBWSFQSMXWNQKB-UHFFFAOYSA-N methyl 5-(4-fluorophenyl)pyrrolidine-2-carboxylate Chemical compound N1C(C(=O)OC)CCC1C1=CC=C(F)C=C1 GBWSFQSMXWNQKB-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- MJLQPFJGZTYCMH-LURJTMIESA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]-5-oxopyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1[C@H](C(O)=O)CCC1=O MJLQPFJGZTYCMH-LURJTMIESA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- XINMCBPQQRMVCJ-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-5-phenylpyrrolidine-2-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC=CC=2)CCC1C(N)=O XINMCBPQQRMVCJ-UHFFFAOYSA-N 0.000 description 1
- VULMHIKCCBLGPL-UHFFFAOYSA-N 1-[2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]ethyl]-1,2,4-triazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCN1N=CN=C1 VULMHIKCCBLGPL-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- KNHUXOTVSKQUQO-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-(methoxymethyl)-1-(4-methylphenyl)sulfonylpyrrolidine Chemical compound COCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 KNHUXOTVSKQUQO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PIACSZZYWMEBFX-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]-n'-hydroxypropanimidamide Chemical compound ONC(=N)C(C)C1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 PIACSZZYWMEBFX-UHFFFAOYSA-N 0.000 description 1
- ZMSIFDIKIXVLDF-UHFFFAOYSA-N 2-methyl-1,3,4-oxadiazole Chemical compound CC1=NN=CO1 ZMSIFDIKIXVLDF-UHFFFAOYSA-N 0.000 description 1
- SNDXULXDUWZRPS-UHFFFAOYSA-N 3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]pentanamide Chemical compound NC(=O)CC(CC)C1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 SNDXULXDUWZRPS-UHFFFAOYSA-N 0.000 description 1
- MNGQWDRNGZEIAC-UHFFFAOYSA-N 3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propanamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCC(N)=O MNGQWDRNGZEIAC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AAHQPLJUSLMHHR-UHFFFAOYSA-N 3-chloro-1-(4-fluorophenyl)propan-1-one Chemical compound FC1=CC=C(C(=O)CCCl)C=C1 AAHQPLJUSLMHHR-UHFFFAOYSA-N 0.000 description 1
- NZUXCIJMBOOMSZ-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]-n'-hydroxybutanimidamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCC(=N)NO NZUXCIJMBOOMSZ-UHFFFAOYSA-N 0.000 description 1
- XBXJBETUMOAWEC-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]butanenitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCC#N XBXJBETUMOAWEC-UHFFFAOYSA-N 0.000 description 1
- LACFLXDRFOQEFZ-UHFFFAOYSA-N 4-ethylbenzenesulfonyl chloride Chemical compound CCC1=CC=C(S(Cl)(=O)=O)C=C1 LACFLXDRFOQEFZ-UHFFFAOYSA-N 0.000 description 1
- YEXGLCNRXQZQHA-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonyl-n-(pyridin-3-ylmethyl)pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C(=O)NCC1=CC=CN=C1 YEXGLCNRXQZQHA-UHFFFAOYSA-N 0.000 description 1
- KSCYAVZGLTYFTP-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C(N)=O KSCYAVZGLTYFTP-UHFFFAOYSA-N 0.000 description 1
- ZKMXPIPSUNXNEI-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-methyl-1-(4-methylphenyl)sulfonylpyrrolidin-2-amine Chemical compound CNC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 ZKMXPIPSUNXNEI-UHFFFAOYSA-N 0.000 description 1
- WLBSAJCQKQSTDU-UHFFFAOYSA-N 5-[2-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]ethyl]-2-methyltetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCC1=NN(C)N=N1 WLBSAJCQKQSTDU-UHFFFAOYSA-N 0.000 description 1
- XUXVVOMSLGFDFJ-UHFFFAOYSA-N 5-[4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]butyl]-2-methyltetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCCC1=NN(C)N=N1 XUXVVOMSLGFDFJ-UHFFFAOYSA-N 0.000 description 1
- VRVBCQBVAJHABX-UHFFFAOYSA-N 5-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]pentanenitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCCC#N VRVBCQBVAJHABX-UHFFFAOYSA-N 0.000 description 1
- PXGUHPWYILFPDH-UHFFFAOYSA-N 5-[[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]methyl]-1-methyltetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CC1=NN=NN1C PXGUHPWYILFPDH-UHFFFAOYSA-N 0.000 description 1
- PKUIYXDGGRGYTI-UHFFFAOYSA-N 5-[[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]methyl]-2-methyltetrazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CC1=NN(C)N=N1 PKUIYXDGGRGYTI-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- AYQBGIHEVFCSQF-UHFFFAOYSA-N C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCN Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCN AYQBGIHEVFCSQF-UHFFFAOYSA-N 0.000 description 1
- MYBRSZIEXAZNKI-UHFFFAOYSA-N C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CNC(=O)C1CC1 Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CNC(=O)C1CC1 MYBRSZIEXAZNKI-UHFFFAOYSA-N 0.000 description 1
- YESXIAMQHTVRNW-UHFFFAOYSA-N C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CNC(=O)C1CCCC1 Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CNC(=O)C1CCCC1 YESXIAMQHTVRNW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 1
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 1
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 1
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101000722185 Oryctolagus cuniculus Corticostatin-2 Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- NUPDTQWJVDWXBY-UHFFFAOYSA-N [1-(4-ethylphenyl)sulfonyl-5-(4-fluorophenyl)pyrrolidin-2-yl]methanol Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CO NUPDTQWJVDWXBY-UHFFFAOYSA-N 0.000 description 1
- YBGJZYCWGNYUMA-UHFFFAOYSA-M [Cl-].[P+]=O Chemical compound [Cl-].[P+]=O YBGJZYCWGNYUMA-UHFFFAOYSA-M 0.000 description 1
- AMJRSUWJSRKGNO-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O AMJRSUWJSRKGNO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 1
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 1
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 1
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- IWXMHLLMQPITOF-UHFFFAOYSA-N methyl 1-(4-ethylphenyl)sulfonyl-5-(4-fluorophenyl)pyrrolidine-2-carboxylate Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1C(=O)OC IWXMHLLMQPITOF-UHFFFAOYSA-N 0.000 description 1
- HECADQPHKHNSIJ-UHFFFAOYSA-N methyl 1-(4-methylphenyl)sulfonyl-5-phenylpyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCC(C=2C=CC=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 HECADQPHKHNSIJ-UHFFFAOYSA-N 0.000 description 1
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
- PLTYXWQEMLQCPO-UHFFFAOYSA-N methyl 5-phenylpyrrolidine-2-carboxylate Chemical compound N1C(C(=O)OC)CCC1C1=CC=CC=C1 PLTYXWQEMLQCPO-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- HBWAZVZSMBRMJP-UHFFFAOYSA-N n-[3-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]propyl]-2,2-dimethylpropanamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCNC(=O)C(C)(C)C HBWAZVZSMBRMJP-UHFFFAOYSA-N 0.000 description 1
- RZRDTLHUCHEPMD-UHFFFAOYSA-N n-[4-[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]butyl]cyclopropanecarboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CCCCNC(=O)C1CC1 RZRDTLHUCHEPMD-UHFFFAOYSA-N 0.000 description 1
- WAKSEQZFMIWLLD-UHFFFAOYSA-N n-[[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]methyl]-2,2-dimethylpropanamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC(F)=CC=2)CCC1CNC(=O)C(C)(C)C WAKSEQZFMIWLLD-UHFFFAOYSA-N 0.000 description 1
- TUFLAXPYDQYQPN-UHFFFAOYSA-N n-[[5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-yl]methyl]acetamide Chemical compound CC(=O)NCC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 TUFLAXPYDQYQPN-UHFFFAOYSA-N 0.000 description 1
- VSNFPSOZIYVONL-UHFFFAOYSA-N n-ethyl-5-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-2-amine Chemical compound CCNC1CCC(C=2C=CC(F)=CC=2)N1S(=O)(=O)C1=CC=C(C)C=C1 VSNFPSOZIYVONL-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LPXCHPSTROLSJX-UHFFFAOYSA-N pentanimidamide Chemical compound CCCCC(N)=N LPXCHPSTROLSJX-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00113894 | 2000-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200209966B true ZA200209966B (en) | 2004-03-09 |
Family
ID=8169121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200209966A ZA200209966B (en) | 2000-06-30 | 2002-12-09 | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders. |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US6589978B2 (fr) |
| EP (1) | EP1299383B1 (fr) |
| JP (1) | JP3994051B2 (fr) |
| KR (1) | KR100529423B1 (fr) |
| CN (1) | CN1178936C (fr) |
| AR (1) | AR029288A1 (fr) |
| AT (1) | ATE286895T1 (fr) |
| AU (2) | AU2001281877B2 (fr) |
| BR (1) | BR0112093A (fr) |
| CA (1) | CA2413243A1 (fr) |
| CZ (1) | CZ2003280A3 (fr) |
| DE (1) | DE60108394T2 (fr) |
| DK (1) | DK1299383T3 (fr) |
| EC (1) | ECSP024403A (fr) |
| ES (1) | ES2234869T3 (fr) |
| HK (1) | HK1058358A1 (fr) |
| HR (1) | HRP20021023B1 (fr) |
| HU (1) | HUP0301167A3 (fr) |
| IL (2) | IL153425A0 (fr) |
| JO (1) | JO2384B1 (fr) |
| MA (1) | MA26923A1 (fr) |
| MX (1) | MXPA02012270A (fr) |
| MY (1) | MY126903A (fr) |
| NO (1) | NO324218B1 (fr) |
| NZ (1) | NZ523025A (fr) |
| PE (1) | PE20020103A1 (fr) |
| PL (1) | PL360396A1 (fr) |
| PT (1) | PT1299383E (fr) |
| RU (1) | RU2272026C2 (fr) |
| SI (1) | SI1299383T1 (fr) |
| TW (1) | TWI265928B (fr) |
| UY (1) | UY26812A1 (fr) |
| WO (1) | WO2002002554A1 (fr) |
| YU (1) | YU99702A (fr) |
| ZA (1) | ZA200209966B (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171614A1 (en) * | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
| DE10240818A1 (de) * | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| GB0225938D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| JP2007531742A (ja) * | 2004-04-05 | 2007-11-08 | シェーリング コーポレイション | 新規のγセクレターゼインヒビター |
| EP1758884A2 (fr) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | Inhibiteurs sulfonamido n-cycliques de gamma-secretase |
| MX2007000040A (es) | 2004-06-30 | 2007-03-07 | Schering Corp | N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas. |
| US7803802B2 (en) * | 2004-07-22 | 2010-09-28 | Schering Corporation | Substituted amide beta secretase inhibitors |
| CA2582777A1 (fr) | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | Inhibiteurs de pompe a protons |
| EP1867641A4 (fr) * | 2005-04-04 | 2010-01-13 | Takeda Pharmaceutical | Médicament prophylactique ou thérapeutique contre la dépression ou la névrose d'angoisse |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (fr) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline |
| ME00610B (fr) | 2005-08-30 | 2011-12-20 | Takeda Pharmaceuticals Co | Dérivés de 1-h-pyrrole substitués par un groupe 1-hétérocyclylsulfonyle, 2-aminométhyle, 5-(hétéro)aryle en tant qu'inhibiteurs des sécrétions acides |
| CA2625153A1 (fr) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation de la neurogenese par inhibition de la pde |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2377531A2 (fr) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogénèse par modulation de l'angiotensine |
| WO2008030651A1 (fr) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinaisons contenant un dérivé de 4-acylaminopyridine |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| DK2066659T3 (da) * | 2006-09-29 | 2013-12-09 | Gruenenthal Gmbh | Substitueret sulfonamid-derivat |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| SI2318006T1 (sl) * | 2008-08-15 | 2017-01-31 | Nivalis Therapeutics, Inc. | Novi pirolni inhibitorji S-nitrozoglutation reduktaze kot terapevtska sredstva |
| MY152008A (en) | 2008-08-27 | 2014-08-15 | Takeda Pharmaceutical | Pyrrole compounds |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| ES2351323B1 (es) * | 2009-06-26 | 2011-10-05 | Institut Univ. De Ciència I Tecnologia, S.A. | Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos. |
| ES2351452B1 (es) * | 2009-07-01 | 2011-10-05 | Institut Univ. De Ciència I Tecnologia, S.A. | Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica. |
| AU2022296214A1 (en) * | 2021-06-25 | 2024-01-25 | Albius Sciences Alpha Private Limited | Heterocycloalkyl-substituted polyheteroazole derivative as medical drug for treatment and/or prevention of rs virus infectious disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905979A (en) * | 1974-05-09 | 1975-09-16 | Stanford Research Inst | Diazabicyclooctanes and diazabicycloheptanes |
| US4539411A (en) * | 1982-02-05 | 1985-09-03 | Hoffmann-La Roche Inc. | Rhodium complexes of chiral phosphines |
| US5036153A (en) * | 1989-05-11 | 1991-07-30 | Braish Tamim F | Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates |
| GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| CA2309338A1 (fr) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Derives d'acide amine cycliques utilises comme inhibiteurs de l'adhesion cellulaire |
| GB9804426D0 (en) | 1998-03-02 | 1998-04-29 | Pfizer Ltd | Heterocycles |
| AT411339B (de) | 1998-05-13 | 2003-12-29 | Fronius Schweissmasch Prod | Verfahren zum steuern eines schweissgerätes und steuervorrichtung hierfür |
| HUP0102532A3 (en) | 1998-06-03 | 2002-06-28 | Gpi Nil Holdings Inc Wilmingto | Aza-heterocyclic compounds used to treat neurological disorders and hair loss and process for their preparation and pharmaceutical compositions containing them |
| BR9916328A (pt) | 1998-12-18 | 2001-10-02 | Schering Corp | Inibidores de transferase de farnesila |
| EA200100815A1 (ru) * | 1999-01-27 | 2002-08-29 | Орто-Макнейл Фармасьютикал, Инк. | Пептидильные гетероциклические кетоны, применимые в качестве ингибиторов триптазы |
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| WO2000071541A1 (fr) * | 1999-05-20 | 2000-11-30 | Dong Wha Pharm. Ind. Co., Ltd. | Derives d'acide quinoleine-carboxylique actifs optiquement presentant des substituts 7-pyrrolidines amenant une activite optique et leur procede de preparation |
| US6143776A (en) * | 2000-02-02 | 2000-11-07 | Sunesis Pharmaceuticals, Inc. | Tosylproline analogs as thymidylate synthase inhibitors |
-
2001
- 2001-06-13 US US09/880,539 patent/US6589978B2/en not_active Expired - Fee Related
- 2001-06-14 TW TWSULFONYL-A patent/TWI265928B/zh not_active IP Right Cessation
- 2001-06-22 JP JP2002507806A patent/JP3994051B2/ja not_active Expired - Fee Related
- 2001-06-22 YU YU99702A patent/YU99702A/sh unknown
- 2001-06-22 AT AT01960365T patent/ATE286895T1/de not_active IP Right Cessation
- 2001-06-22 AU AU2001281877A patent/AU2001281877B2/en not_active Ceased
- 2001-06-22 NZ NZ523025A patent/NZ523025A/en unknown
- 2001-06-22 SI SI200130290T patent/SI1299383T1/xx unknown
- 2001-06-22 BR BR0112093-0A patent/BR0112093A/pt not_active IP Right Cessation
- 2001-06-22 HU HU0301167A patent/HUP0301167A3/hu unknown
- 2001-06-22 WO PCT/EP2001/007135 patent/WO2002002554A1/fr active IP Right Grant
- 2001-06-22 MX MXPA02012270A patent/MXPA02012270A/es active IP Right Grant
- 2001-06-22 DE DE60108394T patent/DE60108394T2/de not_active Expired - Fee Related
- 2001-06-22 EP EP01960365A patent/EP1299383B1/fr not_active Expired - Lifetime
- 2001-06-22 DK DK01960365T patent/DK1299383T3/da active
- 2001-06-22 RU RU2003100516/04A patent/RU2272026C2/ru not_active IP Right Cessation
- 2001-06-22 PT PT01960365T patent/PT1299383E/pt unknown
- 2001-06-22 ES ES01960365T patent/ES2234869T3/es not_active Expired - Lifetime
- 2001-06-22 KR KR10-2002-7017967A patent/KR100529423B1/ko not_active IP Right Cessation
- 2001-06-22 CZ CZ2003280A patent/CZ2003280A3/cs unknown
- 2001-06-22 IL IL15342501A patent/IL153425A0/xx active IP Right Grant
- 2001-06-22 AU AU8187701A patent/AU8187701A/xx active Pending
- 2001-06-22 CN CNB01812061XA patent/CN1178936C/zh not_active Expired - Fee Related
- 2001-06-22 CA CA002413243A patent/CA2413243A1/fr not_active Abandoned
- 2001-06-22 PL PL36039601A patent/PL360396A1/xx unknown
- 2001-06-26 JO JO2001100A patent/JO2384B1/en active
- 2001-06-27 MY MYPI20013048 patent/MY126903A/en unknown
- 2001-06-27 AR ARP010103053A patent/AR029288A1/es not_active Application Discontinuation
- 2001-06-27 PE PE2001000638A patent/PE20020103A1/es not_active Application Discontinuation
- 2001-06-29 UY UY26812A patent/UY26812A1/es not_active Application Discontinuation
-
2002
- 2002-12-09 ZA ZA200209966A patent/ZA200209966B/en unknown
- 2002-12-12 IL IL153425A patent/IL153425A/en not_active IP Right Cessation
- 2002-12-20 HR HR20021023A patent/HRP20021023B1/xx not_active IP Right Cessation
- 2002-12-26 EC EC2002004403A patent/ECSP024403A/es unknown
- 2002-12-27 MA MA26983A patent/MA26923A1/fr unknown
- 2002-12-27 NO NO20026263A patent/NO324218B1/no unknown
-
2003
- 2003-03-26 US US10/397,908 patent/US6995182B2/en not_active Expired - Fee Related
-
2004
- 2004-02-16 HK HK04101071A patent/HK1058358A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200209966B (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders. | |
| AU2001281877A1 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
| US7803822B2 (en) | Triazole derivative and use thereof | |
| JP2002500619A (ja) | 置換ビフェニルイソオキサゾールスルホンアミド | |
| EA021359B1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
| JP6746614B2 (ja) | ウレア誘導体、またはその薬理学的に許容される塩 | |
| CZ20031795A3 (cs) | Fenylethenylové nebo fenylethynylové deriváty jako antagonisté glutamátového receptoru | |
| JP2007526275A (ja) | ペンタフルオロスルファニル化合物、これらの製造、及び医薬品としての使用 | |
| PL204436B1 (pl) | Pochodne 1-arenosulfonylo-2- arylopirolidyny i piperydyny, lek, zastosowanie tych pochodnych oraz sposób ich wytwarzania | |
| WO1997019073A1 (fr) | Derives de piperidine et de tetrahydropyridine | |
| US7875647B2 (en) | Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists | |
| JP2007526274A (ja) | スチリル−アゾールの酸化チオエーテル誘導体及びｈｅｒチロシンキナーゼ阻害因子としてのこれらの使用 | |
| EP2007753B1 (fr) | Modulateurs du récepteur sélectif du sous-type de gaba alpha hétérocyclique | |
| WO2013111796A1 (fr) | Dérivé de pyrazole n-substitué | |
| WO2017057717A1 (fr) | Dérivé hétéroaromatique | |
| US20040236114A1 (en) | Imidazole derivatives as adenosine deaminase inhibitors |